Clinical management of women with metastatic breast cancer: a descriptive study according to age group (original) (raw)
Related papers
Oncological Disease in Metastatic Breast Neoplasia and Palliative Care: A Review
World Journal of Cancer and Oncology Research, 2023
Cancer is the second cause of death worldwide, affecting one in six people, with breast cancer being the most prevalent in females. Adapting to an oncological disease entails many physical and psychological changes that affect the patient and their families. This work aims to present existing scientific research on adaptation to oncological disease and the end of life of women with metastatic cancer aged between 45 and 65, framing with Acceptance and Commitment Therapy. (TAC). Fifty documents with publication dates between 2002 and 2022 were included in this study. It was found that there is much information on the topic in question, as it is a problem that affects not only women but also all the systems they are in. When faced with a terminal diagnosis, a woman faces many doubts and uncertainties, in addition to all the physical effects of the disease. Therefore, she should be accompanied by a team specialized in Palliative Care, which can provide her and her family with all the support needed in this challenging phase.
Cancer, 1986
A retrospective review of 483 women who had metastatic breast cancer and were treated between 1942 and 1975 was carried out to examine the effects of improving and aggressive palliative modalities on patient survival. There was a steady increase in the proportion of patients treated by chemotherapy and/ or hormonal ablative therapy. Additive hormonal therapy, irradiation, and surgery for palliation decreased in frequency during the same period. Survival time from the first recurrence did not appear to increase in these patients over the period of this study. In spite of increasingly sophisticated palliative therapies, the survival time of patients with metastasis did not appear to be significantly prolonged.
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older
Women's Health, 2012
Breast cancer is a disease of aging and the incidence of breast cancer increases dramatically with increasing age. In spite of major advances in prevention, screening and treatment approximately 40,000 Americans still die of metastatic breast cancer every year – the majority being women aged 65 years and older. Metastatic breast cancer remains incurable regardless of age and the goals of treatment are to reduce symptoms when present and to provide the patient with the best quality of life for as long as possible. Cornerstones of treatment to control metastases include endocrine therapy, chemotherapy and radiation therapy. Supportive care that includes psychosocial support and treatment of pain is also a key component of management. This review focuses on the issues related to the care of older women with metastatic breast cancer.
Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer
Iranian journal of cancer prevention, 2008
Purpose: Metastatic breast cancer has remained as an incurable disease. The main objectives of treatments include alleviating of symptoms, delaying disease progression and increasing survival without any adverse effect on the quality of life. The main purpose of this study was to investigate the effects of some clinocopathological factors on the survival of patients with metastatic breast carcinoma in our institute. Patients and Methods: In this retrospective cohort study, we reviewed the files of patients who were metastatic at presentation or became metastatic during follow-up and were referred to oncology department of Omid Hospital affiliated to Mashhad University of Medical Sciences from 1997 to 2007. The information regarding clinicopathological characteristics were recorded. The first line chemotherapy regimen was as follows: 79 CAF (cyclophosphamide, doxurobicine, 5FU), 25 CMF (cyclophosphamide, methotrexate, 5FU) and 11 Taxene based; AT (doxorubicin, paclitaxol) or TAC (taxene, doxurobicine, cyclophosphamide). Results: 115 patients with a median age of 45 (range, 25-78) were investigated. The median follow-up time for all patients from diagnosis was 21 months (range, 5-74 months) and from metastatic manifestation was 12 months (5-36 months). The sites of recurrence or metastasis were as follows: 18 (15.7%) local recurrence, 23(20%) bone and 74 (64.3%) visceral metastases. The median and 2-year overall survival for all patients with metastatic disease were 15 months and 44.6% ± 6% respectively. Patients with bone metastasis had a significantly better overall survival compared to those with visceral metastasis. (74.2%vs.36.1%, P= 0.04) Among those patients who were non-metastatic at the time of referral, the time left to metastasis had a significant effect on the overall survival from metastasis manifestation. In comparison with premenopausal patients, the overall survival was relatively better in postmenopausal cases. (59.4% vs. 38.5%, P=0.1) Conclusion: In our study, disease free survival (DFS) was the most important factor for overall survival in patients with metastatic breast cancer. The patients with longer DFS (>18month) had better overall survival. Overall the patients with bone metastasis had better survival than visceral metastasis.
The importance of palliative care in the treatment of patients with breast cancer: a literature review (Atena Editora), 2024
Palliative care is a practice implemented within the scope of health care, aimed at individuals in intense suffering due to a life-threatening disease, such as breast cancer. Their purpose is to provide relief from the suffering experienced by the patient. The objective of this review was to analyze and expose the demands pertinent to palliative care for patients diagnosed with breast cancer. A search for studies was carried out on the United States National Library of Medicine (PubMed) and Virtual Health Library (VHL) platforms, and a total of 27 scientific articles were included after applying inclusion and exclusion criteria. The results indicate that palliative care is extremely relevant, contributing to the relief of symptoms caused by breast cancer and its treatment, with emphasis on pain as the strongest predictor of quality of life and as a significant impact on the performance of daily activities. Such care should be implemented early, for patients, family members, and companions. In conclusion, health professionals must be aware of the benefits of palliative care and offer it early to breast cancer patients.
Metastatic disease to the breast: the Washington University experience
World Journal of Surgical Oncology, 2007
Background: Metastases to the breast occur rarely, but may be increasing in incidence as patients live longer with malignant diseases. The aim of this study is to characterize metastatic disease to the breast and to describe the management and prognosis of patients who present with this diagnosis.
Mansoura Nursing Journal, 2016
Advanced breast cancer also called metastatic breast cancer, a breast cancer that has extend from the breast to other organs in the body as lungs, liver, bones and brain. Women with advanced breast cancer needs a special care called as a palliative care needs related to psychological, social, spiritual, physical and educational aspects. Aim of the study is to assess palliative care needs of women with advanced breast cancer. Methods:a descriptive cross sectional design was used in this study. A convenient sample of 100 women with advanced breast cancer was selected. TheTool used divided into two parts including demographic data, palliative care needs of women with advanced breast cancer. Setting: This study was conducted in inpatient department and outpatient clinics at Oncology Center Mansoura University (OCMU).Results: The results of this study revealed that women identified the greatest areas of palliative care needs in relation to poor activity of daily living (41%), the majority of the studied women had poor psychologicalissues (98%), all of them had poor financial issues and additional expenses (100%),the highest percentage of them had severe physical issues (85%),about two third of them had poor self-dependence issues (69%) and poor educational issues (73%). Conclusions:This study indicates that women with advanced breast cancer have high levels of palliative care needs, especially in relation to the areas of activity of daily living, psychological, physical, financial, selfdependence and educational issues that requiring interventions aimed at meeting palliative care needs of women with advanced breast cancer. Advanced breast cancer have statistically significant high levels of palliative care needs.
Metastases to breast - A 29 year experience in a tertiary care hospital
The Gulf journal of oncology, 2014
Metastatic lesions to the breast are unusual. We present a series of 26 cases of metastatic tumors to breast from extra-mammary sites over a period of 29 years. There were 14 female and 12 male patients, and their ages ranged from 28 to 70 years. The tumor was in the upper outer quadrant in 16 patients. All 26 cases noticed a mass in the breast and more than half of the patients complained of discomfort and pain. The mammary symptoms were present for more than 4 months in all patients. Of the 26 cases, 13 cases had metastatic adenocarcinoma, 12 cases had metastatic squamous cell carcinoma and one case had poorly differentiated carcinoma. On mammography, 16 patients showed high density lesions and on ultrasonography lesions were hypoechoic. Prognosis is poor but appears slightly improved since more refined chemo and immunotherapeutic regimens were available. The clinical, pathologic, and radiographic features of this problem are described.
Factors associated with mortality after breast cancer metastasis
Cancer Causes & Control, 2012
Background It is generally accepted that patients with breast cancer metastases have very poor survival. Metastatic breast cancer patients can be considered a heterogeneous population with a varied clinical course, which underscores the need for accurate prediction of survival based on prognostic factors. The purpose of the present study was to identify factors related to survival in breast cancer patients after diagnosis with metastatic disease. Populations and methods A total of 557 patients with breast cancer metastasis diagnosis seen at one large urban practice have been followed up between 1 January, 1999 and 30 June, 2010. Demographic, tumor characteristics, clinical factors as predictors of survival were analyzed using log-rank test and Cox regression model. Results The median survival length was 39 months (range 1-138 months) with 154 (27.7%) alive and 403 (72.3%) dead at the end of follow-up period. This study demonstrated that a history of hypertension, ER/PR status, HER2 status, metastasis-free interval, metastatic location (including brain, bone and liver), and BMI at diagnosis with metastatic breast cancer were the most relevant prognostic factors for survival after metastatic disease diagnosis. Conclusion Findings of this study may form a foundation for the growing corpus of knowledge explaining the outcome differences in treatment of patients with metastatic breast cancer, potentially helping to create tailored counseling and personalized treatment approaches for this vulnerable group.
Management of advanced breast cancer
Annals of Oncology, 2007
Metastatic breast cancer (MBC) is usually considered an incurable situation, for which treatments chosen to control the disease, should take into account the maintenance of a good quality of life. The end points of treatment of patients with MBC are influenced by consideration about efficacy and toxicity of the different therapeutic options. The availability of markers predicting response to treatment as well as the discovery of new agents have led to the identification of patients likely to obtain significant advantage from different treatment options. Due to the chronic nature of the MBC, the clinical benefit which encompasses objective response and long stabilization of disease has often become a goal in the metastating setting.